Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with EGFR-TKI in T790M-negative NSCLC
NCT03389256Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Sichuan Cancer Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03389256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03389256.